Chromogenic and fluorescent in situ hybridization in breast cancer

被引：75

作者：

Lambros, Maryou B. K. ^{[1
]}

Natrajan, Rachael ^{[1
]}

Reis-Filho, Jorge S. ^{[1
]}

机构：

[1] Inst Canc Res, Breakthrough Breast Canc Res Ctr, Mol Pathol Lab, London SW3 6JB, England

来源：

HUMAN PATHOLOGY | 2007年 / 38卷 / 08期

关键词：

breast cancer; chromogenic in situ hybridization; fluorescent in situ hybridization; molecular genetics;

D O I：

10.1016/j.humpath.2007.04.011

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Fluorescent (FISH) and chromogenic (CISH) in situ hybridization have recently become part of the diagnostic armamentarium of breast pathologists. HER2 gene testing by FISH and/or CISH has become an integral part of the diagnostic workup for patients with breast cancer. In this era of high throughput technologies, these techniques have proven instrumental for the validation of results from microarray-based comparative genomic hybridization and for the identification of novel oncogenes and tumor suppressor genes. Furthermore, FISH and CISH applied to tissue microarrays have expedited the characterization of genomic changes associated with specific breast cancer molecular subtypes and the identification of novel prognostic and predictive markers. In this review, we provide in this review a critical assessment of CISH and FISH and the impact of the analysis of amplification of specific oncogenes (eg, HER2, EGFR, MYC, CCND1, and FGFR1) and deletion of tumor suppressor genes (eg, BRCA1 and BRCA2) on our understanding of breast cancer. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：1105 / 1122

页数：18

共 194 条

[61] A 1Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes [J].

Garcia, MJ ;

Pole, JCM ;

Chin, SF ;

Teschendorff, A ;

Naderi, A ;

Ozdag, H ;

Vias, M ;

Kranjac, T ;

Subkhankulova, T ;

Paish, C ;

Ellis, I ;

Brenton, JD ;

Edwards, PAW ;

Caldas, C .

ONCOGENE, 2005, 24 (33) :5235-5245

[62] Comprehensive profiling of 8p11-12 amplification in breast cancer [J].

Gelsi-Boyer, W ;

Orsetti, B ;

Cervera, N ;

Finetti, P ;

Sircoulomb, F ;

Rougé, C ;

Lasorsa, L ;

Letessier, A ;

Ginestier, C ;

Monville, F ;

Esteyriès, S ;

Adélaïde, J ;

Esterni, B ;

Henry, C ;

Ethier, SP ;

Bibeau, F ;

Mozziconacci, MJ ;

Charafe-Jauffret, E ;

Jacquemier, J ;

Bertucci, F ;

Birnbaum, D ;

Theillet, C ;

Chaffanet, M .

MOLECULAR CANCER RESEARCH, 2005, 3 (12) :655-667

[63] Lapatinib plus capecitabine for HER2-positive advanced breast cancer [J].

Geyer, Charles E. ;

Forster, John ;

Lindquist, Deborah ;

Chan, Stephen ;

Romieu, C. Gilles ;

Pienkowski, Tadeusz ;

Jagiello-Gruszfeld, Agnieszka ;

Crown, John ;

Chan, Arlene ;

Kaufman, Bella ;

Skarlos, Dimosthenis ;

Campone, Mario ;

Davidson, Neville ;

Berger, Mark ;

Oliva, Cristina ;

Rubin, Stephen D. ;

Stein, Steven ;

Cameron, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) :2733-2743

[64] Prognosis and gene expression profiling of 20q13-amplified breast cancers [J].

Ginestier, Christophe ;

Cervera, Nathalie ;

Finetti, Pascal ;

Esteyries, Sverine ;

Esterni, Benjamin ;

Adelaide, Jose ;

Xerri, Luc ;

Viens, Patrice ;

Jacquemier, Jocelyne ;

Charafe-Jauffret, Emmanuelle ;

Chaffanet, Max ;

Birnbaum, Daniel ;

Bertucci, Francois .

CLINICAL CANCER RESEARCH, 2006, 12 (15) :4533-4544

[65] Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer:: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility [J].

Gong, Y ;

Gilcrease, M ;

Sneige, N .

MODERN PATHOLOGY, 2005, 18 (08) :1015-1021

[66] MYC is amplified in BRCA1-associated breast cancers [J].

Grushko, TA ;

Dignam, JJ ;

Das, S ;

Blackwood, AM ;

Perou, CM ;

Ridderstråle, KK ;

Anderson, KN ;

Wei, MJ ;

Adams, AJ ;

Hagos, FG ;

Sveen, L ;

Lynch, HT ;

Weber, BL ;

Olopade, OI .

CLINICAL CANCER RESEARCH, 2004, 10 (02) :499-507

[67] The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability [J].

Gudmundsdottir, K. ;

Ashworth, A. .

ONCOGENE, 2006, 25 (43) :5864-5874

[68] Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer [J].

Gupta, D ;

Middleton, LP ;

Whitaker, MJ ;

Abrams, J .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (03) :381-387

[69] Biomarkers to predict response to epidermal growth factor receptor inhibitors [J].

Haas-Koogan, DA ;

Prados, MD ;

Lamborn, KR ;

Tihan, T ;

Berger, MS ;

Stokoe, D .

CELL CYCLE, 2005, 4 (10) :1369-1372

[70] Chromogenic in-situ hybridization:: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm [J].

Hanna, WM ;

Kwok, K .

MODERN PATHOLOGY, 2006, 19 (04) :481-487

← 2 3 4 5 6 7 8 9 10 11 →